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ABSTRACT 
Age-related macular degeneration (AMD) is the leading cause of certified vision loss 
worldwide. The standard treatment for neovascular AMD involves repeated intravitreal 
injections of therapeutic proteins directed against vascular endothelial growth factor, such as 
ranibizumab. Biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), form 
delivery vehicles which can be used to treat posterior segment eye diseases, but suffer from 
poor protein loading and release. This work describes a ‘system-within-system’, PLGA 
microparticles incorporating chitosan-based nanoparticles, for improved loading and 
sustained intravitreal delivery of ranibizumab. Chitosan-N-acetyl-L-cysteine (CNAC) was 
synthesized and its synthesis confirmed using FT-IR and 1H NMR. Chitosan-based 
nanoparticles comprised of CNAC, CNAC/tripolyphosphate (CNAC/TPP), chitosan, 
chitosan/TPP (chit/TPP) or chit/TPP-hyaluronic acid (chit/TPP-HA) were incorporated in 
PLGA microparticles using a modified w/o/w double emulsion method. Nanoparticles and 
final nanoparticles-within-microparticles were characterized for their protein-nanoparticle 
interaction, size, zeta potential, morphology, protein loading, stability, in vitro release, in vivo 
anti-angiogenic activity and effects on cell viability. The prepared nanoparticles were 17 – 
350 nm in size and had zeta potentials of -1.4 to +12 mV. Microscopic imaging revealed 
spherical nanoparticles on the surface of PLGA microparticles for preparations containing 
chit/TPP, CNAC and CNAC/TPP. Ranibizumab entrapment efficiency in the preparations 
varied between 13 – 69% and was highest for the PLGA microparticles containing CNAC 
nanoparticles. This preparation also showed the slowest release with no initial burst release 
compared to all other preparations. Incorporation of TPP to this formulation increased the 
rate of protein release and reduced entrapment efficiency. PLGA microparticles containing 
chit/TPP-HA showed the fastest and near-complete release of ranibizumab. All of the 
prepared empty particles showed no effect on cell viability up to a concentration of 12.5 
mg/mL. Ranibizumab released from all preparations maintained its structural integrity and in 
vitro activity. The chit/TPP-HA preparation enhanced anti-angiogenic activity and may 
provide a potential biocompatible platform for enhanced anti-angiogenic activity in 
combination with ranibizumab. In conclusion, the PLGA microparticles containing CNAC 
nanoparticles, showed significantly improved ranibizumab loading and release profile. This 
novel drug delivery system may have potential for improved intravitreal delivery of 
therapeutic proteins, thereby reducing the frequency, risk and cost of burdensome intravitreal 
injections. 
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1. INTRODUCTION  
Age-related macular degeneration (AMD) accounts for more UK blindness than all other eye 
diseases combined (1). There are approximately 26,000 new cases of wet AMD in the UK 
every year (2). Wet AMD is the most aggressive form and is usually treated with protein or 
aptamer-based therapy directed against vascular endothelial growth factor (VEGF); 
ranibizumab (Lucentis), bevacizumab (Avastin) or aflibercept (Eylea). The efficacy of these 
agents is limited by their short half-lives, necessitating repeated administration of expensive 
intravitreal injections (IVTs) (4) that are associated with rare but sight-threatening 
complications such as retinal detachment and endophthalmitis (5). Further, they undergo 
hydrolytic breakdown by enzymes present in the vitreous and have been reported to have 
stability issues secondary to protein aggregation upon storage, which can potentially affect 
the preparation’s shelf-life (6, 7). Therefore, there is a high demand for developing a 
biodegradable sustained-release delivery vehicle with high protein loading and maintained 
protein stability. Further, the physicochemical properties, such as the size and size 
distribution, of the delivery vehicle influence formulation reproducibility, dose uniformity 
and suitability for IVT (8). One candidate vehicle is PLGA microparticles. These are FDA 
approved, biodegradable drug delivery systems which have been used extensively for the 
controlled delivery of proteins (9, 10) and intravitreal corticosteroids like Ozurdex® (Allergan 
Inc., Irvine, CA, USA). However, these delivery vehicles suffer from limitations like poor 
protein stability, loading, an initial burst release and non-uniform particle sizes (11-13). Studies 
have addressed these limitations by altering process parameters like polymer concentration, 
solvent composition, stabiliser concentration and the incorporation of additives (14, 15). 
However, this usually overcomes only one or two limitations.  
 
This study describes a ‘system-within-system’, comprised of chitosan-based nanoparticles 
within PLGA microparticles for intravitreal delivery of ranibizumab. Chitosan was chosen as 
it is a biodegradable, biocompatible polymer with potential to improve the physicochemical 
properties of PLGA microparticles and offers additional anti-angiogenic activity (18, 19), 
potentially enhancing the therapeutic effect of ranibizumab. There are many reported 
mechanisms for the anti-angiogenic activity of chitosan which vary with the type, molecular 
weight (MW) and concentration of chitosan used as well as the target cell type. It has been 
reported to inhibit endothelial cell migration (20) and tumour invasion (21).  Recently, chitosan 
has also been shown to inhibit lipopolysaccharide (LPS)-induced interleukin-8 (IL-8) 
production in endothelial cells involved in the pathogenesis of vascular diseases (22). 
Although some studies have reported the opposite effect, namely angiogenesis (23-25). 
 
Hyaluronic acid (HA) is a viscous polyanion which constitutes a major portion of the human 
vitreous humor (26) and has been used previously for sustained protein delivery (27). What is 
more, as with chitosan, high molecular weight (Mw) HA has also been shown to exhibit anti-
angiogenic activity (28) and has shown favourable physicochemical properties when used to 
coat chit/TPP nanoparticles, such as reducing size polydispersity, increasing zeta potential 
and improving particle size stability (29). Given these properties, HA was assessed in this 
study for its effects on PLGA-based ranibizumab delivery.  
 
A chemically-modified derivative of chitosan, chitosan-N-acetyl-L-cysteine (CNAC) was 
also used to prepare nanoparticles and compare their effects with unmodified chitosan-based 
nanoparticles on PLGA-based ranibizumab delivery. CNAC differs to unmodified chitosan 
by containing N-acetyl-L-cysteine (NAC) which introduces a thiol group that has been shown 
to form strong disulphide bonds with cysteine-rich domains of the mucus glycoproteins 
accounting for stronger mucoadhesive properties compared to chitosan (30). Therefore, it may 
be postulated that the NAC component of CNAC forms strong disulphide bonds with the 10 
cysteine residues present in ranibizumab (31) enhancing nanoparticle-protein interactions and 
improving loading and release of ranibizumab in PLGA microparticles. Further, VEGF has 8 
cysteine residues (32), therefore, CNAC may introduce additive anti-angiogenic activity via 
VEGF binding and consequent neutralization. Indeed, NAC has been reported to have anti-
angiogenic activity and targets multiple pathways involved in angiogenesis including 
oxidation and inflammation (33, 34). Given NAC and chitosan’s anti-angiogenic activity, we 
hypothesized that CNAC would enhance the anti-angiogenic activity of ranibizumab.  
 
Sodium tripolyphosphate (TPP) was used as a crosslinking agent with chitosan, CNAC and 
chitosan/HA to form uniformly-distributed stable nanoparticles (35). Chitosan/TPP (chit/TPP) 
nanoparticles have shown good ocular biocompatibility.  
 
We aimed to develop chitosan-based nanoparticles within PLGA microparticles for improved 
intravitreal delivery of ranibizumab. 
 
2. EXPERIMENTAL SECTION 
 
2.1 Materials 
The following materials were commercially obtained and used as received: hyaluronic acid 
sodium salt (Mw 1.5–1.8 × 106 Da, from Streptococcus equi, Fluka BioChemika, St. Louis, 
Mo, USA), chitosan hydrochloride (chitosan, Mw; ≤ 400 kDa, DDA 80 – 95%, Heppe 
Medical, Halle, Germany), PLGA  (85 : 15 DL, Mw 149 kDa, Alkermes Medisorb, 
Wilmington Ohio, USA), ranibizumab (Novartis, Frimley, UK), Recombinant human 
vascular endothelial growth factor 165 (VEGF, PeproTech, NJ, USA), goat anti-human IgG 
F(ab’)2 antibody:horseradish peroxidase (HRP, SeroTech, Oxford, UK), 
tetramethylbenzidine (TMB) substrate and TMB stop reagent (Surmodics/BioFX 
Laboratories, Eden Prairie, USA), Laemmli sample buffer (BioRad, Herts, UK), 2-
mercaptoethanol (98%, Lancaster Synthesis, Lancs., UK), Coomassie Brilliant Blue stain 
(BioRad Laboratories, Inc., California, USA), low-growth factor synthetic matrix (Matrigel, 
BD Bioscience, San Jose, CA), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine methosulfate (PMS) (CellTiter 96® 
AQueous One solution, Promega, Madison, WI) and mouse tumour (BD Biosciences, 
Bedford, UK). The following were purchased from Life Technologies (Paisley, Scotland, 
UK): TrypLE™ Express (1X, trypsin, EDTA, phenol red), SYTO® 9 and propidium iodide. 
The following materials were obtained from Fisher (Leicestershire, UK): sodium hydroxide 
(NaOH), glacial acetic acid, methanol, sodium chloride, sodium hydrogen carbonate, 
potassium chloride and potassium dihydrogen orthophosphate. The following materials were 
obtained from Sigma-Aldrich (St Louis, MO, USA): sodium acetate (anhydrous), polyvinyl 
alcohol (PVA, 87-89% hydrolysed, Mw: 13-23 kDa), D-(+)-trehalose dehydrate, 1-Ethyl-3-
(3-Dimethylaminopropyl) carbodiimide, hydrochloride (EDAC•HCl), NAC, crystal violet 
(dye content ≥ 90 %), bovine serum albumin (BSA), Tween 20, cetylpyridinium chloride, 
sodium azide, calcium chloride, sodium tripolyphosphate, Ham’s F-10 medium (pH 7.4), 
anhydrous dimethylsulfoxide (DMSO, > 99.9%), Dulbecco's phosphate-buffered saline 
(DPBS), L-glutamine 200 mM, foetal bovine serum (FBS), antibiotic-antimycotic solution 
(100 units/mL penicillin, 100 µg/mL streptomycin and 25 ng/mL amphotericin B), M199 
medium, porcine gelatine, porcine heparin, endothelial cell growth supplement, Triton-X and 
sodium dodecyl sulphate (SDS) The following materials were obtained from VWR 
International (Lutterworth, UK): magnesium sulphate, di-sodium hydrogen phosphate 
dehydrate and dichloromethane (DCM, stabilised with 0.2% of ethanol). The water used 
throughout all of the experimental procedures was ultrapure water. 
 2.2 Synthesis of CNAC 
CNAC was synthesised as described previously (36), with slight modifications. Briefly, 6 g of 
chitosan was dissolved in 100 mL of acetate buffer (pH 4.5) at room temperature. 24 g of 
NAC plus 8.64 g of EDAC•HCl was dissolved in 100 mL of acetate buffer under continuous 
stirring for 30 minutes and nitrogen atmosphere. NAC solution was then added to the 
chitosan solution and left to stir overnight at 4ºC under nitrogen atmosphere. This was then 
dialyzed (MWCO; 12-14 kDa, Medicell International, London, UK), in the dark, for 5 days 
and lyophilized to obtain the CNAC powder.  
 
2.3 1H NMR and Fourier-transform-infrared (FT-IR) spectroscopy 
1H NMR spectra for CNAC and its native constituents (chitosan and NAC) was recorded on a 
Bruker 400 MHz Ultrashield NMR spectrometer (Bruker Avance, Rheinstetten, Germany).  
IR spectra for these components and the prepared nanoparticles were recorded on a 
PerkinElmer Spectrum 100 FT-IR spectrometer (spectral range of 4000 to 400 cm-1 
PerkinElmer, Waltham, MA).  
 
2.4 Preparation of chitosan-based nanoparticles containing ranibizumab 
Chitosan-based nanoparticles containing ranibizumab were prepared to be added to PLGA 
microparticles (Section 2.6). The nanoparticles were composed of chitosan, chitosan/TPP 
(chit/TPP), chit/TPP-HA, CNAC or CNAC/TPP. 0.5% w/v chitosan or CNAC solution was 
prepared in 5% w/v PVA/acetate buffer (pH 5). 5 mg of ranibizumab (drug-containing 
nanoparticles) or an equivalent volume of water (empty particles), was added dropwise to this 
solution and left to stir for 15 minutes. Water (for chitosan or CNAC particles) or 0.05% w/v 
TPP solution (for chit/TPP, chit/TPP-HA or CNAC/TPP) was added dropwise and left to stir 
for a further 45 minutes. Chit/TPP-HA nanoparticles were prepared by adding 0.25% w/v of 
HA solution at the end. The composition of the resultant nanoparticles was chitosan (or 
CNAC):ranibizumab:TPP:HA in a ratio of 10:10:1:5.  
 
2.5 Characterization of chitosan-based nanoparticles 
 
2.5.1 Particle size and zeta potential 
A Malvern Zetasizer Nano ZS (Malvern Instruments Ltd, Worcestershire, UK) instrument 
which utilizes dynamic light scattering (DLS) and laser Doppler velocimetry (LDV) was used 
to measure the size and zeta potential of the particles, respectively. 
 
2.5.2 Morphological examination of chitosan-based particles using transmission electron 
microscopy (TEM) 
Approximately 40 µL of the each preparation was placed on a copper grid, covered with 
nitrocellulose and negatively stained with 1% uranyl acetate. Images were obtained using a 
FEI CM 120 Bio Twin transmission electron microscope (Philips Electron Optics BV, 
Netherlands). 
 
2.6 Preparation of a system-within-system, composed of chitosan-based nanoparticles-
within-PLGA microparticles  
Chitosan-based nanoparticles were added to PLGA microparticles using the w/o/w double 
emulsion method (36), with modifications. Briefly, 100 mg of PLGA was dissolved in 2.5 mL 
of DCM. 1 mL of primary aqueous phase containing the chitosan-based nanoparticles 
(Section 2.4) was added to this and the suspension homogenised (Ultra Turrax T25 basic, Ika-
Werke, Staufen, Germany) at 21 krpm for 2 minutes. The resultant primary emulsion was 
added to 3 mL of secondary continuous phase composed of 1% w/v PVA plus 0.5% w/v of 
empty chitosan-based nanoparticles, prepared as outlined in Section 2.4. To avoid creating a 
concentration gradient which would act as driving force for diffusion, affecting the drug 
entrapment efficiency and release (37) a similar concentration of nanoparticles was used in 
the primary phase and continuous phase for all of the preparations. The mixture was 
homogenised for a further 2 minutes. Solvent extraction was carried out by mixing at room 
temperature for 3 hours. The resultant particles were washed by centrifugation (Optima L-
90K Ultracentrifuge, Beckman Coulter, Fullerton, CA) at 4°C, 21 krpm for 25 minutes. The 
supernatants from these washes were used to quantify the free ranibizumab content. 
 
2.7 Characterization of nanoparticle-within-microparticle drug delivery system 
 
2.7.1 Particle size and zeta potential 
Particles were measured for their size using laser diffraction (Malvern Mastersizer S long 
bench, Malvern, UK) and zeta potential using LDV as outlined in Section 2.5.1.  
 
2.7.2 Scanning electron microscopy (SEM) 
Approximately 2 mg of lyophilized sample was placed onto a metal stub and sputter coated 
with 20 nm of gold using a Quorum Q150 (Quorum Ltd, UK). This was viewed using a 
scanning electron microscope (FEI Quanta 200F, Eindhoven, The Netherlands). 
 
2.8 Determination of ranibizumab entrapment efficiency 
The ranibizumab entrapment efficiency was calculated by measuring the difference between 
the amount of protein added and the free protein in the supernatant of the preparation, as 
outlined previously (38, 39). Indirect ELISA was used for the quantification of ranibizumab. 
Briefly, high-binding 96-well plates (Greiner Microlon High Binding, Greiner Bio-One, 
Frickenhausen, Germany) were coated with 1 µg/mL of VEGF and incubated overnight at 
4°C. The plates were then washed twice with PBS and blocked with 1% w/v BSA and then 
washed a further two times with 5% Tween 20/PBS, after which, the ranibizumab standards 
and samples were added. The plates were then incubated for 2 h at 37°C and washed again 
with 5% w/v Tween 20/PBS. This was followed by the addition of 1:4000 HRP detection 
antibody and incubation for 1 h at 37°C. The wash step was repeated followed by the addition 
of TMB substrate plus a 30 min incubation. The reaction was stopped using the stop reagent 
and the absorbance read at 450 nm using a microplate ultra-violet spectrophotometer 
(Synergy HT, Bio-Tek Instruments, VT, USA).  
 
2.9 In vitro ranibizumab release studies   
Ranibizumab released from the prepared particles was determined using the separation 
technique (40), by suspending the PLGA pellet in 10 mL of release medium containing Hanks’ 
balanced salt solution (HBSS), pH 7.4 and 0.05% w/v sodium azide. This buffer was 
prepared as described previously (41). The suspension was placed in air-tight containers and 
incubated at 37 °C with mild continuous agitation (80 rpm, orbital incubator, Gallenkamp; 
Loughborough, UK). At predetermined time intervals (ranging from 30 mins up to 7 months), 
the pH was measured to ensure minimal changes and the suspension centrifuged at 13 krpm 
for 15 mins. The supernatant containing the released ranibizumab was collected and 
quantified using ELISA (Section 2.8). The pellet was re-suspended in fresh release medium 
and re-incubated. The average cumulative ranibizumab released was plotted against time.  
 
 
 
2.10 Analysis of the structural integrity of ranibizumab released from PLGA microparticles 
The structural integrity of ranibizumab released from PLGA microparticles was analysed 
using SDS-PAGE, as previously described (42), with modifications. Equivalent amounts of 
native and released ranibizumab (quantified using a BCA kit, Micro BCA Protein Assay, 
Pierce, Rockford, IL) were treated with sample buffer containing 2-mercaptoethanol and 
Laemmli buffer for 5 mins at 95 °C. The samples were then loaded onto polyacrylamide gels 
(Any KdTM) along with Precision Plus protein standard (both from BioRad, Herts, UK). 
Electrophoresis was performed at a constant voltage of 150 V for 45 mins (Bio-Rad power 
PAC 1000, Melville, NY). Protein bands were stained using Coomassie Brilliant Blue stain 
for analysis. 
 
2.11 Cell studies 
The safety of the nanoparticles-within-microparticles was assessed by analyzing their effect 
on mitochondrial activity via MTS assay and for any changes in cell morphology using the 
Live/Dead assay. Human retinal pigment epithelial (ARPE-19, American Type Culture 
Collection, VA, USA) cells and human vascular endothelial cells (HUVECs, Caltag 
Medsystems, Buckingham, UK) lines were used in this study. ARPE-19 cells were cultured 
in Ham’s F-10 medium (pH 7.4), supplemented with 2 mM glutamine, antibiotic-antimycotic 
solution and 10% heat-inactivated fetal bovine serum (FBS). HUVECs were grown on cell 
culture flasks pre-coated with 0.1% porcine gelatin and maintained in M199 medium (pH 
7.4) supplemented with 20% FBS, 2 mM L-glutamine, 100 µg/ml porcine heparin, 50 µg/ml 
endothelial cell growth supplement and antibiotic-antimycotic solution. The culturing 
medium for both HUVEC and ARPE-19 cells is referred to as complete growth medium 
(CGM). Both cell lines were cultured in a humidified chamber set at 37°C and 5% CO2 
atmosphere. 
 
2.11.1 In vitro cytotoxicity studies  
The effect of native ranibizumab and empty PLGA microparticles on the viability of ARPE-
19 and HUVECs was determined using CellTiter 96® AQueous One solution (MTS) assay. A 
qualitative analysis of this effect was also carried out using fluorescence microscopy 
(Live/Dead assay) to investigate the effects, if any, of the samples on the morphology of the 
cells. 96-well plates were seeded with 2 x 104 cells/mL using CGM and incubated for 48 h 
before being replaced with low-serum (2% FBS) media and incubated for a further 12 h. 
Native ranibizumab (7.63 x105 - 2.5 mg/mL) and empty PLGA microparticles (3.81 x 104 - 
12.5 mg/mL), together with the controls (negative: 1% Triton X and positive: untreated 
media) were added to the plate and incubated for a further 24 hours. Following the incubation 
period the MTS assay was conducted according to manufacturer's instructions, absorbance 
read (UV spectrophotometer, Synergy HT, Bio-Tek Instruments, VT, USA) and data 
normalized to untreated cells. Live/Dead assay was performed by exposing the cells to native 
ranibizumab and empty PLGA microparticles containing chitosan-based nanoparticles for 24 
hours. A mixture of 3.34 µM SYTO® 9 and 5 µg/mL propidium iodide was then added and 
fluorescent images obtained (EVOS fluorescence microscope, Lifetech, UK).  
 
2.11.2 Assessment of anti-angiogenic activity 
 
2.11.2.1 Effect of ranibizumab released from PLGA microparticles on endothelial cell 
migration 
Endothelial cell migration is a key process involved in angiogenesis (43). Therefore, the anti-
angiogenic activity of ranibizumab released from PLGA microparticles was assessed by 
analyzing inhibition of VEGF-stimulated HUVEC migration as described in (44), with 
modifications. HUVECs were trypsinized at 70% confluence and resuspended in low serum 
medium. Cells were then seeded (4 x 105 cells/mL) onto matrigel-coated transwell inserts 
(8.0 μm polycarbonate membrane, 6.5mm, Corning Costar, Cambridge, UK) and placed into 
lower chambers containing M199 medium supplemented with 10% FBS, 10 ng/mL VEGF 
(negative control) and 125 µg/mL of native ranibizumab (positive control) or ranibizumab 
released from PLGA microparticles. The released ranibizumab was collected as previously 
described (45) and concentrated to 125 µg/mL using centrifugal concentrators (10 kDa 
MWCO, Vivaspins, Vivascience, Hannover, Germany) which were spun at 4 krpm, 4 °C,  for 
15 mins (Centrifuge 5804R, Eppendorf, Germany). 125 µg/mL of ranibizumab was selected 
to represent the therapeutic concentration following injection into the human vitreous. The 
plate was then incubated for 20 h at 37°C and 5% CO2 atmosphere. Following the incubation 
period, non-migrated cells were removed using a cotton swab, inserts washed twice with PBS 
and migrated cells fixed using absolute methanol. The migrated cells were stained using 0.5% 
crystal violet, viewed using a light microscope (Nikon Microphot-FXA, Nikon, Tokyo, 
Japan) and quantified by counting the number of cells in six random fields per insert. Images 
were captured using a Nikon digital camera (Nikon, Kingston upon Thames, UK) and 
processed using Infinity Capture application (version 6.2). Data was expressed as the 
percentage of cells/field (mean ± S.D, n=6) migrated in the presence of ranibizumab relative 
to the VEGF control. 
 
2.11.2.2 Effect of released chitosan and chit/TPP particles with or without ranibizumab on 
capillary-like tubule formation  
Chit/TPP-HA nanoparticles showed the highest anti-angiogenic effect and as a result was 
taken further to be assessed using the capillary-like tubule formation assay (V2a kit, TCS 
Cellworks, Buckingham, UK). Cells were exposed to VEGF (2 ng/mL) plus 125 µg/mL of 
native ranibizumab or ranibizumab plus chit/TPP or chit/TPP-HA nanoparticles or equivalent 
concentrations of empty nanoparticles. VEGF (promotes angiogenesis) and 20 µM suramin 
(inhibits angiogenesis) were used as the negative and positive controls, respectively. Wells 
were viewed using a Leitz Diavert phase contrast microscope and images captured using a 
Nikon digital camera (Nikon, Kingston upon Thames, UK). The images were then processed 
using Infinity Capture application (v. 6.2, Lumenera Corp., Canada) and tubules quantified 
using AngioSys 2.0 software (v. 1.0.0.2, TCS Cellworks, Buckingham, UK) for their length 
as previously described (46, 47). Data was presented as the total tubule length relative to the 
VEGF control, for each sample (mean ± S.D, n=3).  
   
2.12 Statistical analysis 
Statistical analysis was carried out on all data using two-way analysis of variance (ANOVA) 
and unpaired two-tailed student t-test. A p value of < 0.05 was taken to be significant. Data 
are presented as the mean ± standard deviation (SD) from 3 independent studies, unless 
otherwise stated. 
 
3. RESULTS AND DISCUSSION  
 
3.1 Confirmation of CNAC synthesis 
 
3.1.1 Confirmation of CNAC synthesis using FTIR 
Fig. 1 shows the FT-IR spectra for the synthesised CNAC polymer and its native constituents 
NAC and chitosan. CNAC showed an increase in the intensity of the absorption peak at 1638 
(amide I band), 1520 (amide II band) and 1311 (amide III) cm-1 compared to native chitosan. 
This is ascribed to the presence of an additional amide bond from the NAC group (48), 
confirming the successful synthesis of CNAC.  
 
Fig. 1. FT-IR spectra for the synthesised CNAC polymer and its native constituents, chitosan and NAC. 
Abbreviations: NAC; N-acetyl-L-cysteine and CNAC; chitosan-N-acetyl-L-cysteine. 
 
3.1.2 Proton nuclear magnetic resonance (1H NMR) 
The 1H NMR spectra of CNAC (Fig. 2C) shows peaks at 2.91 and 1.97 ppm which confirm 
the synthesis of this polymer. The peak at 2.91 ppm corresponds to the conjugated NAC 
group ‘CH2SH’ replacing the N-acetyl methyl proton seen in chitosan at 2.14 ppm (Fig. 2B). 
This correlates with recent findings (48). The successful conjugation of the NAC group to 
chitosan was further confirmed by a peak at 1.97 ppm which was present in both NAC (Fig. 
2A) and CNAC (Fig. 2C) and corresponds to the methyl proton present in both entities (49). 
These findings, together with the FT-IR results, confirm the successful synthesis of the 
CNAC polymer. 
 Fig. 2. 1H NMR spectra of NAC (A), chitosan (B) and CNAC (C). Samples were dissolved at a concentration of 
8 mg/mL in D2O. Grey line indicates water content. Abbreviations: NAC; N-acetyl-L-cysteine and CNAC; 
chitosan-N-acetyl-L-cysteine. 
 
3.2 Characterization of chitosan-based nanoparticles 
Particle size, distribution, zeta potential and morphology of the nanoparticles constituting the 
primary aqueous phase of the preparation were analyzed as these parameters influence the 
stability of the primary emulsion and subsequently the protein loading and release (50).  
 
 
3.2.1 Particle size and zeta potential 
Fig 3 shows the particle size (Fig 3A) and zeta potential (Fig. 3B) of the prepared 
nanoparticles. The size was relatively similar to another study utilizing nanoparticles in 
PLGA microparticles which reported a nanoparticle size of 513 nm (50). Empty chit/TPP 
particles were significantly larger than chitosan particles (345.5 ± 2.5 and 40.1 ± 3 nm, 
respectively, p = 1.79 x 10-8) and previously reported chit/TPP particles of sizes up to 226 
nm (51). This is due to the use of a higher chitosan Mw and chit/TPP ratio of 10:1 compared 
4:1 (51) as these parameters have been reported to influence the particle size (52). Conversely, 
CNAC/TPP nanoparticles had a significantly smaller size of 71.8 ± 5.6 nm (p = 4.77 x 10-6) 
compared to chit/TPP particles and previously reported CNAC/TPP nanoparticles of 166.3 
nm (48). Although a higher chitosan Mw was used in this study compared to Wang’s study 
(Mw ≤ 400 kDa and 20 kDa, respectively) (48), the smaller particles obtained in this study 
may be due to the type of chitosan salt used as this has also been shown to influence the size 
(52). This is further confirmed by comparing CNAC nanoparticles prepared from a different 
chitosan salt with a similar Mw to that which is used in this study; they obtained a larger size 
of 214 ± 10 nm compared to 25.7 ± 2.6 nm (53). The reason behind the significantly (p = 
0.003) smaller size of CNAC nanoparticles compared to the chitosan particles was the 
stronger intermolecular interactions resulting from CNAC’s thiol group (53, 54). The 
incorporation of HA with chit/TPP did not influence the particle size significantly (chit/TPP-
HA; 350.7 ± 2.5 nm) compared to chit/TPP (345.5 ± 2.5 nm; p = 0.11) but was larger than 
previously-reported HA chitosan nanoparticles (163 - 182 nm) (55, 56). Native Ranibizumab 
had a size of 8.37 ± 0.2 nm which is in line with a previous study (57). Entrapping 
ranibizumab in the chitosan-based nanoparticles had varying effects with a decrease in size 
obtained for chitosan and CNAC/TPP particles and an increase in size obtained for the 
chit/TPP-HA nanoparticles. This may be due to a difference in the interaction between the 
protein and the nanoparticles.  
 
Particle zeta potential is shown in Fig. 3B. The charge of native ranibizumab was near neutral 
charge, at + 0.44 ± 1.5 mV and is in line with a previous study (22). Particle zeta potential was 
predominantly positive as a result of the polycation, chitosan (58-60). This decreased with the 
CNAC nanoparticles due to the NAC component and is in agreement with a previous study 
(48). A further decrease in the positive zeta potential was observed for the chit/TPP-HA 
nanoparticles as a result of the polyanion, HA. However, the polyanion, TPP had different 
effects on the zeta potential of chitosan and CNAC nanoparticles, where there was a further 
decrease in the positive zeta potential of CNAC/TPP particles and no effect on the zeta 
potential of chit/TPP nanoparticles. This may have been due to stronger electrostatic 
interactions from the NAC component in CNAC with the TPP compared to the unmodified 
chitosan with TPP. Entrapment of ranibizumab in all of the nanoparticles caused a reduction 
in the zeta potential. This demonstrates ranibizumab binding to the chitosan component and is 
further confirmed by FT-IR (Fig. 5) 
 
 
 
 Fig. 3. Particle size (A) and zeta potential (B) of native ranibizumab and chitosan, chit/TPP, CNAC, CNAC/TPP 
and chit/TPP-HA with and without ranibizumab. Data are presented as the mean ± SD, n = 3. Error bars show 
the standard deviation. Abbreviations: r: ranibizumab, C: chitosan, C/T: chit/TPP, chit/T-HA: chit/TPP-HA, 
CNAC/T: CNAC/TPP, CNAC; chitosan-N-acetyl-L-cysteine, HA: hyaluronic acid and TPP: tripolyphosphate. 
 
3.2.2 Nanoparticle morphology  
Fig. 4 shows TEM micrographs for the chitosan-based nanoparticles containing ranibizumab. 
The particle sizes appeared smaller than those reported in DLS (Section 3.2.1) as TEM 
generates images for particles in their dry state, whereas DLS measures the particle size in 
their swollen state (61, 62). However, the general trend stands, where CNAC and CNAC/TPP 
nanoparticles are smaller than all of the other nanoparticles. Both chitosan (Fig. 4) and 
CNAC (Fig. 4) nanoparticles had anisometric morphologies. TPP complexation with chitosan 
(Fig. 4Cx) or CNAC (Fig. 4Ex) caused the formation of nanoparticle islands of approximately 
150 nm sizes containing smaller nanoparticles. This has been noted previously for chit/TPP 
nanoparticles (35, 63) but not for the CNAC/TPP nanoparticles (48) which appeared smaller 
compared to the chit/TPP nanoparticles (approximately 6 nm and 12-30 nm, respectively). 
Further inspection of the chit/TPP sample revealed novel ‘globule-like’ nanoparticles (Fig. 
4Cxx) with approximate sizes of 300 nm containing smaller nanoparticles. Chit/TPP-HA (Fig. 
4D) nanoparticles appeared spherical as reported previously (56). All of the particles were 
uniformly-distributed with no signs of aggregates, under TEM.  
     
 
 
Fig. 4. TEM images of ranibizumab (A) and the following ranibizumab-containing particles: chitosan (B), 
chit/TPP (C, Cx, Cxx), chit/TPP-HA (D), CNAC (E, Ex) and CNAC/TPP (F). Abbreviations: chit/TPP; 
chitosan/tripolyphosphate, chit/TPP-HA; chitosan/tripolyphosphate-hyaluronic acid, CNAC; chitosan-N-acetyl-
L-cysteine and CNAC/TPP; chitosan-N-acetyl-L-cysteine/tripolyphosphate. 
 
3.2.3 Particle-protein interaction  
Ranibizumab (Fig. 5A) showed absorption peaks at 995, 1037 and 1085 cm-1 corresponding 
to =C-H bending, C-F and C-O stretching, respectively (64). These peaks were visible in the 
spectra for chitosan, chit/TPP and chit/TPP-HA (Fig. 5B), as well as CNAC and CNAC-TPP 
(Fig. 5C) containing ranibizumab. Thus, confirming the presence of an interaction between 
these particles and ranibizumab. An interaction between the P=O group of TPP and NH3+ 
present in the chitosan-based particles was apparent by the increased peak intensity at 1180 
cm-1 (65). The absorption peaks at 1625 cm-1 (amide I, CO stretching) and 1516 cm-1 (amide 
II, CN stretching, NH bending) of the chit/TPP-HA preparation confirms an interaction 
between the amino groups in chitosan and the carboxyl groups in HA (66). 
 
 
 
Fig. 5. FT-IR spectra for: r, TPP and HA (A), chitosan, chit/TPP and chit/TPP-HA particles with and without r 
(B) and  CNAC and CNAC/TPP particles with and without r (C). Abbreviations: r: ranibizumab, chit/TPP; 
chitosan/tripolyphosphate, chit/TPP-HA; chitosan/tripolyphosphate-hyaluronic acid, CNAC; chitosan-N-acetyl-
L-cysteine and CNAC/TPP; chitosan-N-acetyl-L-cysteine/tripolyphosphate. 
 
3.3 Characterization of nanoparticle-within-microparticle drug delivery system 
 
3.3.1 Particle size and zeta potential 
The size (Fig. 6) of the nanoparticle-within-microparticle drug delivery system was measured 
to assess the suitability for IVT. The particle sizes were in the range of 3.04 – 6.04 µm which 
is considerably smaller than previously reported particles of sizes 14 – 21 μm (9, 67) which 
showed no effects on the retinal in vivo studies. Thus, based on the size, the particles appear 
to be suitable for IVT. The particle size distribution is also in good agreement with the SEM 
studies (Section 3.3.2). There was no difference in the size of the PLGA particles containing 
chitosan (p = 0.06), chit/TPP (p = 0.08) or chit/TPP-HA (p = 0.82) nanoparticles. However, 
the PLGA particles containing CNAC were significantly smaller than the control (p = 0.005) 
and chitosan (p = 0.0045). This is likely attributed to the NAC component which may have 
increased the osmotic pressure inside the PLGA matrix, preventing inward diffusion of water 
molecules (68). This may also account for the higher protein entrapment (Section 3.4) and 
slower release (Section 3.5). The addition of ranibizumab did not influence the size of the 
PLGA microparticles, with exception to those containing CNAC/TPP nanoparticles where an 
increase in the size was obtained relative to CNAC-containing microparticles (p = 0.0009) 
and the control (p = 0.004). This results from a difference in the protein-nanoparticle 
interaction and may account for the lower protein entrapment efficiency (Section 3.4) and 
higher release (Section 3.5) obtained with the CNAC/TPP preparation relative to the CNAC 
preparation.  
 
Fig. 6 shows the zeta potential of the preparations. The use of chitosan increased the positive 
zeta potential of the overall system (- 12.2 ± 2 mV control compared to + 4.3 ± 1.6 mV, p = 3 
x 10-4). The presence of TPP in the preparations did not influence the zeta potential of 
chitosan-containing preparations but reduced the positive zeta potential in CNAC/TPP 
compared to PLGA microparticles containing chit/TPP (p = 0.049) or CNAC (p = 0.03). This 
may be due to additive effect of two negatively-charged groups (TPP combined with the thiol 
group in CNAC).  
 
 
Fig. 6. Particle size (µm) and zeta potential (mV). Data are represented as the mean ± S.D., n = 3. Error bars 
show the standard deviation. Abbreviations: r; ranibizumab, chit/TPP; chitosan/tripolyphosphate, chit/TPP-HA; 
chitosan/tripolyphosphate-hyaluronic acid, NAC; N-acetyl-L-cysteine and CNAC; chitosan-N-acetyl-L-cysteine. 
 
3.3.2 Particle morphology assessed using SEM 
Fig. 7A shows the morphology of the synthesized polymer and drug delivery systems. At low 
magnification, the CNAC polymer has a shard-like appearance (Fig 7A). However, upon 
closer inspection (Fig.7 Ax), a well-defined interior of nanoparticles closely stacked together 
is apparent. These represent CNAC nanoparticles as it has the ability to self-assemble (53). A 
difference in the particle morphology has been reported to result in different drug release 
profiles (69). The PLGA control (Fig.7B) was mostly-spherical and non-uniformly-sized 
microparticles with an average size of 5 µm. These were smaller but had a similar surface 
morphology to previous findings (70). The addition of chitosan (Fig 7C) formed a layered coat 
(70, 71) with the presence of rod-shaped entities (Fig. 7Cx) on the surface of the microparticles 
and was similar to previous findings (70).  
 
 
        
 
Microparticles containing chit/TPP (Fig. 7D) had a similar morphology to these. However, 
the surface was coated with nanoparticles (Fig. 7Dx) of similar morphology (Fig. 7Dxx) and 
size distribution (DLS, Section 3.2.1) as chit/TPP nanoparticles, suggesting that these PLGA 
microparticles may be coated with the chit/TPP nanoparticles. A similar outcome was 
observed with the microparticles containing chit/TPP-HA (Fig. 7E), CNAC (Fig. 7F) and 
CNAC/TPP (Fig. 7G). However, the coating of the CNAC particles (Fig. 7Fx) appeared to 
differ in morphology to these particles and this difference may have contributed to the 
improved ranibizumab loading and prevention of the initial burst release. All other particles 
had an initial burst release with those of similar morphologies (chit/TPP, chit/TPP-HA and 
CNAC/TPP) having similar and higher rates of ranibizumab release relative to the control 
and chitosan-containing PLGA microparticles.    
 
 
Fig. 7. Scanning electron microscopy images for CNAC polymer (A and Ax) and PLGA microparticles 
containing: no additions (control) (B), chitosan (C and Cx), chit/TPP (D and Dx and chitosan particles alone: 
Dxx), chit/TPP-HA (E), CNAC (F and Fx) and CNAC/TPP (G). Abbreviations: chit/TPP; 
chitosan/tripolyphosphate, chit/TPP-HA; chitosan/tripolyphosphate-hyaluronic acid, CNAC; chitosan-N-acetyl-
L-cysteine and CNAC/TPP; chitosan-N-acetyl-L-cysteine/tripolyphosphate. 
 
3.4 Ranibizumab entrapment efficiency  
Fig. 8 shows the ranibizumab entrapment efficiency in the drug delivery systems. The 
unmodified PLGA microparticles contained 29 ± 3.8% ranibizumab which was similar to 
previous studies reporting an entrapment efficiency in the range of 31 - 44 % (13, 72). The 
addition of chitosan nanoparticles caused a decrease ranibizumab entrapment efficiency (13 ± 
2.0%, p = 0.04). Previous studies have shown both an increase (70) and decrease (48) in protein 
entrapment efficiency as a result of chitosan incorporation. This may be due to a difference in 
the type and Mw of chitosan used. For example, a study which used a chitosan with a much 
larger Mw (1000 kDa compared to ≤ 400 kDa used in this study) reported an increase in 
protein entrapment (70). The use of TPP in chit/TPP, chit/TPP-HA and CNAC/TPP did not 
affect the entrapment efficiency of ranibizumab relative to the control (p = 0.25, 0.89 and 
0.14, respectively). Similar results were also obtained for the morphology and protein release 
of these particles indicating that TPP has similar interactions with the unmodified and NAC-
modified form of chitosan. However, the CNAC particles had the highest ranibizumab 
entrapment efficiency of 69 ± 14%. This is in agreement with another study which reported 
improved drug loading of 62 – 76% as a result of CNAC (73). The enhanced ranibizumab 
entrapment efficiency is as a result of the NAC component as this is the single entity which 
differentiates the particles. The reason behind this effect is yet to be elucidated, however 
three postulations may be put forward. First, CNAC nanoparticles increase the hydrophilicity 
(74) and improve ranibizumab solubilization and entrapment within the particles compared to 
the chitosan or chit/TPP nanoparticles (30, 53). Second, the thiol group present in the NAC 
component of the CNAC nanoparticles has been reported to form strong disulphide bonds 
with the cysteine residues of mucus glycoproteins (30). As ranibizumab contains 10 cysteine 
residues (31), it is anticipated that CNAC will form stronger interactions with ranibizumab 
retaining it inside the PLGA microparticles and minimizing loss during preparation. This 
effect may also contribute to the absence of an initial burst release and slower release 
compared to all of the other preparations (Section 3.5). Finally, CNAC is more viscous than 
chitosan (36) and studies have shown that increasing the viscosity of the PLGA matrix 
improves protein loading (75).  
 
 
Fig. 8. Ranibizumab entrapment efficiency in PLGA (control) and PLGA microparticles containing chitosan-
based particles. Data are presented as the mean ± SD, n = 3. Error bars show the standard deviation. 
Abbreviations: chit/TPP; chitosan/tripolyphosphate, chit/TPP-HA; chitosan/tripolyphosphate-hyaluronic acid, 
NAC; N-acetyl-L-cysteine and CNAC; chitosan-N-acetyl-L-cysteine. 
 
3.5 Protein release from PLGA microparticles  
The in vitro release of ranibizumab was investigated to determine the effect of incorporating 
the chitosan-based nanoparticles in the PLGA microparticles (Fig. 9). The PLGA control 
showed a biphasic response as previously reported (76, 77), with an initial burst release 
followed by a sustained-release period. The addition of chitosan did not alter the release 
profile but increased the rate of protein release as reported previously (78-80). Microparticles 
containing chit/TPP showed a triphasic release profile with a higher initial rate of release 
relative to the control. Further, chit/TPP-HA and CNAC/TPP both showed monophasic 
release with highest initial rate and content of release. The higher protein release obtained for 
chit/TPP, chit/TPP-HA and CNAC/TPP is likely attributed to the nanoparticle presentation on 
the microparticles and protein-nanoparticle interaction. On the other hand, PLGA 
microparticles containing CNAC showed a similar biphasic release profile compared to 
control and chitosan but was considerably lower and was the only formulation which had no 
initial burst release. Previous studies have also obtained release profiles for CNAC particles 
with no initial burst release (53, 54). This is because CNAC has higher viscosity compared to 
chitosan (36) creating a viscous microenvironment which favours sustained delivery (81). 
Another possible reason may be due to the presence of a thick coat, apparent in SEM (Section 
3.3.2, Fig. 7Fx) as this has been reported to reduce the burst-release effect (82). In summary, 
CNAC has improved the release profile of PLGA microparticles providing a potential 
platform for sustained intravitreal delivery of ranibizumab. PLGA microparticles containing 
chit/TPP-HA or CNAC/TPP may be used for the delivery of ocular drugs required for an 
immediate response.  
 
 
Fig. 9. Ranibizumab release from PLGA microparticles. Data are presented as the mean ± SD, n = 3. Error bars 
show the standard deviation. Abbreviations: chit/TPP; chitosan/tripolyphosphate, chit/TPP-HA; 
chitosan/tripolyphosphate-hyaluronic acid, NAC; N-acetyl-L-cysteine and CNAC; chitosan-N-acetyl-L-cysteine. 
 
The concentration of ranibizumab which has been shown to neutralize VEGF in vitro is 120 
ng/mL (83). No toxic effects were obtained following exposure of ranibizumab to HUVECs 
and ARPE-19 cells and up to a concentration of 2.5 mg/mL in the MTS assay (Section 
3.7.1.1). In the first hour, all preparations released 2.21 -35.7 µg/mL of ranibizumab and the 
maximum concentration released was 44.2 -207 µg/mL. Given that these values are all above 
120 ng/mL (and below 2.5 mg/mL) and that ranibizumab released from all of the preparation 
was shown to have maintained its activity (shown by SDS-PAGE and the migration assay, 
Sections 3.6 and 3.7.2.1), it can be concluded that the released ranibizumab will elicit its 
therapeutic effect with no toxic effects. 
3.6 Analysis of the structural integrity of ranibizumab released from PLGA microparticles 
Fig. 10 shows the structural integrity of native ranibizumab and ranibizumab which has been 
released from the preparations. Native ranibizumab showed a distinctive band at 23 kDa 
corresponding to the reduction and cleavage of the disulfide bond between the two chains of 
the Fab fragment (6). This band was also present for ranibizumab released from all of the 
preparations, indicating that the method of preparation and nanoparticles used did not alter 
the structural integrity and affect the stability of this protein. The band smearing may be a 
result of the high salt content from the release medium. 
 
   
Fig. 10. SDS-PAGE band patterns for: native ranibizumab (R) and ranibizumab released from PLGA 
microparticles containing chitosan-based nanoparticles 
 
 
3.7 Cell studies 
 
3.7.1 Cell viability  
 
3.7.1.1 MTS assay  
Safety of ranibizumab (Fig. 11A) and the nanoparticle-within-microparticle preparations was 
assessed by evaluating their effects on mitochondrial activity of ARPE-19 cells (Fig. 11B) 
and HUVECs (Fig. 11C). A higher viability was obtained in HUVECs compared to ARPE-19 
across all of the formulations and may be due to differences in cell sensitivities. Ranibizumab 
was well tolerated in both cell lines up to concentrations of 2.5 mg/mL (Fig. 11A), higher 
than the total concentration loaded in the microparticles. The biocompatibility of PLGA is 
well established in in vitro (84) and in vivo (85, 86) studies with reported safe concentrations of 
up  to 25 mg/mL (87). 12.5 mg/mL of PLGA control was used in this study and showed 80 – 
109% cell viability across both cell lines. Chitosan or CNAC preparations did not 
significantly reduce the cell viability in both cell lines compared to control (p = 0.15 and 
0.07, respectively). Chitosan has been shown to have different safety profiles, varying with 
the type, Mw, zeta potential of the chitosan or the cell type used (88-91). There was also no 
significant difference on cell viability between CNAC and chitosan (p = 0.56) or CNAC/TPP PLGA Microparticle  
(p = 0.95). The addition of HA did not influence the cell viability significantly (p = 0.79), as 
reported in recent studies (92).  
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Fig. 11. Effect of ranibizumab (A) and system-within-system on the viability of ARPE-19 cells (B) and 
HUVECs (C). The cell viability was assessed using the MTS assay following a 24 hour exposure to 
ranibizumab. Data are presented as the mean ± SD, n = 9. Error bars show the standard deviation. 
Abbreviations: chit/TPP; chitosan/tripolyphosphate, chit/TPP-HA; chitosan/tripolyphosphate-hyaluronic acid, 
CNAC; chitosan-N-acetyl-L-cysteine and CNAC/TPP; chitosan-N-acetyl-L-cysteine/ tripolyphosphate. For 
color interpretation, the reader is referred to the online version of this article. 
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3.7.1.2 Live/Dead assay 
The Live/Dead cell viability assay was conducted to provide a qualitative confirmation for 
the MTS viability assay as well as to show the effects, if any, of the drug delivery systems on 
the morphology of HUVECs (Fig 12A) and ARPE-19 cells (Fig 12B) (93). Untreated ARPE-19 
cells (positive controls, fluorescently-labelled green) have a cobblestone-like morphology 
with tight intercellular junctions (93-95). HUVECs have a more spaced distribution with 
cobblestone-like appearance (96, 97). Dead cells appear fluorescently-labelled red. The 
proportion of viable cells reflects the findings from the MTS assay with no morphological 
changes observed across the HUVECs for any of the preparations. However, ARPE-19 cells 
exposed cells to PLGA microparticles containing chitosan, CNAC and CNAC/TPP 
nanoparticles showed a more scattered appearance. This could be secondary to a loss of tight 
cell junctions which has been reported with chitosan as a result of induction and 
redistribution of cytoskeletal F-actin and tight junction protein Zona occludens (ZO-1) (98). 
NAC has recently been reported to causes disassembly of the actin cytoskeleton (99) and 
therefore, this may also contribute to the loss of tight junctions. 
 
 
 
 
 
 
(A) 
 
Fig. 12. Live/Dead micrographs for HUVECs (A) and ARPE-19 cells (B) exposed to 25 mg/mL of native 
ranibizumab and 12.5 mg/mL of empty PLGA microparticles. Green fluorescence indicates living cells, while 
red fluorescence indicates dead cells. Controls used were: media-treated cells (positive control) and cells treated 
with; 1% Triton-X (negative control). Abbreviations: chit/TPP; chitosan/tripolyphosphate, chit/TPP-HA; 
chitosan/tripolyphosphate- hyaluronic acid, CNAC; chitosan-N-acetyl-L-cysteine and CNAC/TPP; chitosan-N-
acetyl-L-cysteine//tripolyphosphate. For color interpretation, the reader is referred to the online version of this 
article. 
 
3.7.2 Assessment of anti-angiogenic activity 
VEGF stimulates angiogenesis via multiple cellular pathways including endothelial cell 
migration (43), proliferation (43)and capillary tube formation(43, 100). Ranibizumab acts by 
binding to VEGF and inhibiting these effects (83, 101). Therefore, ranibizumab released from 
the preparations were analyzed for their anti-angiogenic activity using VEGF-induced cell 
migration and capillary-like tubule formation assays. Further, chitosan-based nanoparticles 
which were found to elicit an anti-angiogenic effect were further assessed using the capillary-
like tubule formation assay. 
 
3.7.2.1 Effect of ranibizumab released from PLGA microparticles on endothelial cell 
migration 
The effect of ranibizumab, released from the prepared PLGA microparticles, on the VEGF-
induced cell migration is shown in Fig. 13. A qualitative depiction of these results is shown in 
Fig. 14. Native ranibizumab showed an approximately five-fold decrease in VEGF-induced 
migration, consistent with previous reports (102). Ranibizumab released from the PLGA 
control particles showed a similar outcome (p = 0.9) indicating that entrapment and release 
did not alter the activity of this protein significantly. This is in agreement with the SDS-
PAGE findings (Section 3.6) showing preserved structural integrity of the released protein. 
(B) 
Studies utilizing PLGA for hydrophilic drug delivery have reported both maintained activity 
(9, 103, 104) and reduced protein stability (11, 105, 106) which result from differences in process 
parameters and the hydrophilic agent used. Ranibizumab released from PLGA microparticles 
containing CNAC and CNAC/TPP showed a slightly higher anti-migratory activity compared 
to ranibizumab released from control (p = 0.16 and 0.4, respectively). The NAC component 
may have contributed to this as it has previously been shown to inhibit VEGF-induced 
HUVEC tubule formation (107). It may be postulated that this effect is secondary to disulfide 
interactions between the cysteine groups of NAC and VEGF(32), however, future studies 
should be conducted to confirm this. Further, NAC has been associated with anti-angiogenic 
activity in various other studies (33). There was no significant difference between the anti-
migratory effects of CNAC and CNAC/TPP (p = 0.91), suggesting that complexation of 
CNAC with TPP does not influence the effect caused.  
 
Chitosan and chit/TPP nanoparticles (Fig. 13D & E, respectively) did not enhance the anti-
migratory activity of ranibizumab opposing the enhanced anti-angiogenic effect obtained in 
the capillary-like tubule formation assay (Section 3.7.2.2). The anti-migratory activity of 
chitosan is not yet fully understood, with studies reporting both pro- and inhibitory effects on 
cell migration (23, 108, 109). However, the difference in the anti-angiogenic activity between the 
two assays may be due to two reasons. First, a cell-specific effect, as the capillary-like tubule 
formation assay has additional human dermal fibroblasts and chitosan has been shown to 
inhibit tubule formation secondary to matrix metalloproteinase-2 inhibition in this cell line 
(21). Another possible explanation, is that this assay considers the later stages of the 
angiogenic process which the migration assay does not take into account (110). However, 
ranibizumab in the chit/TPP-HA-containing (Fig. 13A) preparation showed significantly 
higher anti-migratory activity compared to the control (p = 6.51 x 10-7) (Fig. 13F), which was 
in line with the results of the capillary-like tubule formation assay (Section 3.7.2.2). The anti-
migratory effect could be associated with the HA component of the nanoparticles and is in 
line with a previous study (111). Another recent study (112), showed a dose dependent 
inhibition, with 50% inhibition of migration with HA concentrations as low as 25 µg/mL. 
Although the concentration of chit/TPP-HA (or chit/TPP) nanoparticles released with 
ranibizumab was not quantified, the initial concentration used, assuming nothing was lost, 
was 625 µg/mL of this biocompatible polymer, therefore only 4% of this preparation was 
required to have an effect. Fig. 14 shows light micrographs of migrated HUVECs, stained 
with crystal violet representing a qualitative depiction of the results discussed. As Chit/TPP-
HA showed the highest anti-migratory activity, it was taken forward, together with its 
controls (chitosan and chit/TPP), to confirm anti-angiogenic activity using a different assay 
i.e. capillary-like tubule formation assay. 
 
 
Fig. 13. HUVEC migration for cells exposed to: VEGF/FBS 10% (V/F) and VEGF/FBS 10% plus: native 
ranibizumab (r) or ranibizumab released from: PLGA (A), PLGA + CNAC (B) and PLGA + CNAC/TPP (C), 
PLGA + chitosan (D), PLGA + chit/TPP (E) or PLGA + chit/TPP-HA (F). Results are expressed as the number 
of cells exposed to ranibizumab per visual field (mean ± SD, n = 6) as a percentage of VEGF-stimulated 
migration. Error bars show the standard deviation. Abbreviations: FBS; fetal bovine serum, chit/TPP; 
chitosan/tripolyphosphate, chit/TPP-HA; chitosan/tripolyphosphate-hyaluronic acid, CNAC; chitosan-N-acetyl-
L-cysteine and CNAC/TPP; chitosan-N-acetyl-L-cysteine/tripolyphosphate. 
 
 
Fig. 14. Light micrographs showing migrated HUVECs for untreated cells (2% FBS) and cells exposed to: VEGF/FBS 10% (V/F), native ranibizumab (r) and ranibizumab released 
from: PLGA microparticles (A), PLGA + chitosan (B), PLGA + chit/TPP (C), PLGA + chit/TPP-HA (D), PLGA + CNAC (E) and PLGA + CNAC/TPP (F). Abbreviations: FBS; 
(B) 
fetal bovine serum, chit/TPP; chitosan/tripolyphosphate, chit/TPP-HA; chitosan/tripolyphosphate-hyaluronic acid, CNAC; chitosan-N-acetyl-L-cysteine and CNAC/TPP; chitosan-N-
acetyl-L-cysteine/tripolyphosphate. 
3.7.2.2 Effect of released chitosan and chit/TPP particles with or without ranibizumab on 
capillary-like tubule formation  
Chit/TPP-HA nanoparticles showed the most significant effect in the migration study. 
Therefore, empty and ranibizumab-containing chit/TPP-HA and chit/TPP nanoparticles were 
assessed for their inhibitory effect, if any, on VEGF-induced tubule growth (Fig. 15). 
Suramin standard, an inhibitor of tubule growth, caused 93 ± 0.3% tubule length inhibition 
which was similar to a recent study, reporting 90% inhibition (113). Native ranibizumab has 
been shown to cause a 50 - 70% inhibition of tubule formation at a therapeutic concentration 
of 125 – 200 µg/mL (102, 114, 115). This is similar to the ranibizumab used in this study showing 
an inhibition of 61 ± 4.5%. Empty chit/TPP nanoparticles caused a 30 ± 1.2% inhibition, 
which more than doubled with the addition of ranibizumab showing a statistically significant 
(p = 3.73 x 10-3) improvement in VEGF-mediated anti-angiogenic activity for the 
ranibizumab-loaded nanoparticles. The anti-angiogenic activity of chit/TPP nanoparticles 
may be due to their influence on VEGFR-2 levels in human dermal fibroblasts, as recently 
reported (19). The empty chit/TPP-HA nanoparticles caused a higher inhibition of tubule 
growth relative to chit/TPP nanoparticles (p = 6.09 x 10-4). This is in agreement with previous 
studies which have demonstrated anti-angiogenic activity following exposure to high Mw HA 
(28, 116). The addition of ranibizumab to these nanoparticles demonstrated a higher inhibition 
relative to the chit/TPP-containing ranibizumab and native ranibizumab alone (76 ± 4.6% 
compared to 66 ± 3.5% and 61 ± 4.5%, respectively) and is in line with the migration assay 
findings.  
 
. 
 
Fig. 15. Effects of empty and ranibizumab-containing chit/TPP and chit/TPP-HA nanoparticles on cell tubule 
length inhibition relative to VEGF-treated cells. Data are presented as the mean ± SD, n = 3. Error bars show the 
standard deviation. Abbreviations: r; ranibizumab, chit/TPP; chitosan/tripolyphosphate and chit/TPP-HA; 
chitosan/tripolyphosphate-hyaluronic acid. 
 
4. CONCLUSION 
The standard of care for the most prevalent macular diseases including wet AMD, diabetic 
macular oedema and retinal vein occlusion, necessitates relatively frequent IVT injections, 
owing to the short intravitreal half-lives of the therapeutic proteins; ranibizumab, 
bevacizumab and aflibercept. There is an unmet need for the development of a drug delivery 
system with a high entrapment efficiency and slow release of these agents. PLGA 
microparticles present a suitable platform for intravitreal delivery of ranibizumab as they are 
biodegradable, have a safe ocular profile and have been FDA-approved for the sustained 
intravitreal delivery of dexamethasone (Ozurdex®). However, these microparticles are 
commonly associated with poor protein loading, loss of protein stability and an initial burst 
release, which other studies have attempted to overcome by altering the process parameters 
but have not succeeded in addressing all factors collectively.  
 
Our study analysed the effects of incorporating chitosan-based nanoparticles containing 
ranibizumab within the PLGA microparticles on the loading, stability, activity and release of 
the ranibizumab, as well as their effects on the physicochemical properties of the PLGA 
microparticles. PLGA microparticles containing CNAC nanoparticles significantly improved 
ranibizumab loading, avoiding the initial burst release and a favourable prolonged release 
profile. These effects were perhaps related to the NAC group present in the chitosan 
derivative and may be as a result of the thiol interaction between the cysteine residues of 
NAC and ranibizumab. However, more studies are required to further investigate this. This 
CNAC/PLGA system-within-a-system provides a possible platform for sustained intravitreal 
delivery of ranibizumab, potentially reducing the frequency of IVT and the burden of care. 
Complexation of chitosan or CNAC with TPP increased the rate of release significantly. 
Therefore, these can be used to provide an immediate therapeutic effect of an intravitreal 
protein. Chit/TPP-HA nanoparticles showed enhanced anti-angiogenic activity (enhanced 
anti-migratory activity and inhibition of capillary tube formation) due to the HA component. 
However, PLGA microparticles containing these nanoparticles showed the fastest rate of 
degradation, providing a platform for immediate drug release.  
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